Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.
3.
4.
5.
6.

A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein.

Tychopoulos M, Corcos L, Genne P, Beaune P, de Waziers I.

Cancer Gene Ther. 2005 May;12(5):497-508.

PMID:
15746946
7.

Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer.

Kan O, Griffiths L, Baban D, Iqball S, Uden M, Spearman H, Slingsby J, Price T, Esapa M, Kingsman S, Kingsman A, Slade A, Naylor S.

Cancer Gene Ther. 2001 Jul;8(7):473-82.

8.
9.

Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.

Jounaidi Y, Hecht JE, Waxman DJ.

Cancer Res. 1998 Oct 1;58(19):4391-401.

11.
12.

Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model.

Chen CS, Jounaidi Y, Su T, Waxman DJ.

Cancer Gene Ther. 2007 Dec;14(12):935-44. Epub 2007 Sep 14.

13.

Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.

Chen L, Waxman DJ.

Curr Pharm Des. 2002;8(15):1405-16. Review.

PMID:
12052216
14.

Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect.

Zhou D, Lu Y, Steiner MS, Dalton JT.

Antimicrob Agents Chemother. 2000 Oct;44(10):2659-63.

15.

Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma.

Braybrooke JP, Slade A, Deplanque G, Harrop R, Madhusudan S, Forster MD, Gibson R, Makris A, Talbot DC, Steiner J, White L, Kan O, Naylor S, Carroll MW, Kingsman SM, Harris AL.

Clin Cancer Res. 2005 Feb 15;11(4):1512-20.

16.
18.

Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy.

Günther M, Waxman DJ, Wagner E, Ogris M.

Cancer Gene Ther. 2006 Aug;13(8):771-9. Epub 2006 Mar 17.

PMID:
16543915
19.

Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo.

Nguyen TA, Tychopoulos M, Bichat F, Zimmermann C, Flinois JP, Diry M, Ahlberg E, Delaforge M, Corcos L, Beaune P, Dansette P, André F, de Waziers I.

Mol Pharmacol. 2008 Apr;73(4):1122-33. doi: 10.1124/mol.107.042861. Epub 2008 Jan 22. Erratum in: Mol Pharmacol. 2008 Jun;73(6):1866.

Items per page

Supplemental Content

Write to the Help Desk